Longer treatments could help further characterize the effects of co-exposure between sucrose and arsenic, as well as the relevance of arsenic-induced CAPN1 alterations in the development of MASLD induced by arsenic. Here, CAPN1 is linked to metabolic dysfunction-associated steatotic liver disease.